April 1st 2021
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
September 12th 2012
August 29th 2012
Orgasm quality affected by RP, improves with PDE-5
May 12th 2004Male orgasmic quality can be adversely affected by prostate cancer surgery.However, early treatment with PDE-5 inhibitors may not only improve erectilefunction but orgasmic function as well, according to research from New YorkUniversity.
Analysis shows 'herbal' ED products contaminated with PDE-5 inhibitors
May 11th 2004Some "herbal" products marketed as having efficacy similarto PDE-5 inhibitors without the side effects and the need for medical monitoringactually contain pharmacologic concentrations of PDE-5 inhibitors, accordingto the results of a Canadian study presented here. Separately, Britishresearchers confirmed what many urologists already know-that informationabout herbal ED therapies sold on the Internet is unreliable and misleading.
TCC missed in apparent interstitial cystitis patients
May 10th 2004Today, many patients with apparent interstitial cystitis receive diagnosesbased on the minimally invasive (but not very specific) potassium sensitivitytest and the pelvic pain urgency/frequency (PUF) questionnaire-not throughcystoscopy and hydrodistension under anesthesia, which has been the goldstandard. That means that when the irritative voiding symptoms are in factcaused by transitional cell carcinoma of the bladder, they can be misdiagnosedas IC.
Investigational bulking agent for SUI provides durable efficacy at1 year
May 10th 2004After 1 year of follow-up, women with stress urinary incontinence treatedwith an investigational bulking agent containing ethylene vinyl alcoholdissolved in a dimethyl sulfoxide carrier (EVOH/DMSO, Uryx) are demonstratingdry and improved outcomes more often than controls receiving injectablecollagen (Contigen), investigators from a multicenter study reported yesterday.
Prostate cancer treatment outcomes, robotic techniques grabbing headlinesat this year's AUA
May 9th 2004Over the next 5 days, urologists can expect to hear a great deal aboutprostate cancer treatment outcomes, robotic and minimally invasive surgicaltechniques, pelvic pain in both men and women, the obesity epidemic andits connection to prostate cancer, and advances in erectile dysfunctiontherapy. These are among the key areas of scientific research grabbing headlinesat this year's AUA annual meeting, said J. Brantley Thrasher, MD, chairof AUA's Public Media Committee.Dr. Thrasher briefed a small group of journalists yesterday on theseand other significant topics that make up part of the nearly 2,000 researchpapers being presented here.
FDA approves two-drug combination for BPH
May 9th 2004The FDA has approved changes to the prescribing information for finasteride(Proscar) based on results of the landmark Medical Therapy of ProstaticSymptoms (MTOPS) study. Under the new approval, finasteride administeredin combination with doxazosin (Cardura) is indicated to reduce the riskof symptoms of BPH from progressing over time (a confirmed rise of fouror more points in AUA symptom score). MTOPS showed that the two-drug combinationsignificantly reduced the risk of BPH symptoms progressing versus placeboand versus either finasteride or doxazosin alone.
Sequential monotherapy yields poor results in men with chronic prostatitis
May 9th 2004Today, standard practice for treating chronic prostatitis/chronicpelvic pain syndrome (CP/CPPS) is to try one treatment and, if that fails,move on to the next. It may be time to change this practice, said J. CurtisNickel, MD.
Antibiotic and alpha-blocker found ineffective for chronic prostatitis
May 9th 2004A commonly prescribed antibiotic and alpha-blockerappear to be ineffective in the treatment of men with moderate to severechronic prostatitis/chronic pelvic pain syndrome of long duration. Bothciprofloxacin and tamsulosin-used primarily in the treatment of UTI andBPH, respectively-offered no significant benefit in the treatment of chronicprostatitis in patients who were heavily pretreated and had long-standingsymptoms, a multicenter study shows.
Adjuvant therapy in PCa: Answers are on the horizon
May 1st 2004The use of hormone therapy in most patients with advanced prostate cancerproduces a dramatic positive response followed by a disappointing progression.In many cases, this occurs because treatment is withheld until late in thedisease. Can the grim prognosis of advanced prostate cancer be altered throughthe use of novel agents? Or can outcomes be improved by delivering hormonaltherapy earlier in the disease? The answers are likely yes, as two articlesin this issue of Urology Times suggest (see pages 13 and 24). But the solutionsare not imminent.
New screening guidelines suggest PSA cutoff of 2.5
May 1st 2004Hollywood, FL--The National Comprehensive Cancer Network (NCCN) has issuednew prostate cancer screening guidelines with several significant changes.The new guidelines suggest, but do not unequivocally mandate, screeningall men aged 50 years and older who have a greater than 10-year life expectancyand initiating biopsies if PSA exceeds 2.5 ng/mL.
Proteomics will yield precise therapeutic target
April 25th 2004Before beginning any discussion of advanced prostate cancer, it is importantto point out that early detection of the disease has dramatically reducedthe cohort of men who present with locally advanced or metastatic disease.A review of the Eastern Virginia Medical School database indicates that,of the 320 new diagnoses of prostate cancer in 2003, only 5% presented withstage T3 disease, and 7% presented with stage M+ disease.
MTOPS, AUA guidelines continue to shape BPH Tx
April 25th 2004Dallas--The two most significant developments in the management of benignprostatic hyperplasia in the past year were the release of the AUA updateof clinical guidelines for the condition and analysis of data from the MedicalTherapy of Prostatic Symptoms (MTOPS) trial, said Claus G. Roehrborn, MD,professor and chairman of the department of urology, University of TexasSouthwestern Medical Center, Dallas.
Role of immunology in UTI becoming increasingly clear
April 15th 2004It is becoming increasingly clear that immunology plays a large role in urinary tract infections and potentially in their cure. One new theory is that bacteria can influence the host's immune response by down-regulating it, suppressing the immune system and preventing the host from responding in a normal way.
Men at risk of prostate cancer take precautions, study shows
April 15th 2004Brothers of diagnosed prostate cancer patients are aware of the increased risk of possibly developing prostate cancer and have taken complementary or alternative medicine associated with prostate health as a result, according to a study by the University of Michigan Health System published in Cancer (2004;100:1537-44).
Anticholinergic appears to reduce urgency severity
April 1st 2004Florence, Italy--The anticholinergic drug trospium chloride seemsto reduce urgency severity among patients with overactive bladder, accordingto the results of a prospective investigation by researchers from NorthwesternUniversity, Feinberg School of Medicine, Evanston, IL.
Oral Rx for stress incontinence closer to approval
April 1st 2004Sydney, Australia--Duloxetine, a selective serotonin and norepinephrinereuptake inhibitor, yields significant improvements in incontinent episodesand quality of life among women with stress urinary incontinence, and ispoised to become the first effective oral agent for the condition, an Australianurologist says.